These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8527710)

  • 21. Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.
    Nishida C; Uto H; Oketani M; Tokunaga K; Nosaki T; Fukumoto M; Oku M; Sogabe A; Moriuchi A; Ido A; Tsubouchi H
    J Gastroenterol; 2010 Mar; 45(3):326-34. PubMed ID: 19890604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticotropin-releasing hormone expression in patients with intrahepatic cholestasis of pregnancy after ursodeoxycholic acid treatment: an initial experience.
    Zhou F; Zhang L; He MM; Liu ZF; Gao BX; Wang XD
    Curr Med Res Opin; 2014 Aug; 30(8):1529-35. PubMed ID: 24665980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
    Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
    J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa.
    Cacciarelli TV; Martinez OM; Gish RG; Villanueva JC; Krams SM
    Hepatology; 1996 Jul; 24(1):6-9. PubMed ID: 8707283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.
    Poupon RE; Bonnand AM; Queneau PE; Trépo C; Zarski JPí ; Vetter D; Raabe JJ; Thieffin G; Larrey D; Grangé JD; Capron JP; Serfaty L; Chrétien Y; St Marc Girardin MF; Mathiex-Fortunet H; Zafrani ES; Guéchot J; Beuers U; Paumgartner G; Poupon R
    Scand J Gastroenterol; 2000 Jun; 35(6):642-9. PubMed ID: 10912666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C.
    Kakumu S; Takayanagi M; Iwata K; Okumura A; Aiyama T; Ishikawa T; Nadai M; Yoshioka K
    J Gastroenterol Hepatol; 1997 Jan; 12(1):62-6. PubMed ID: 9076626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.
    Rostaing L; Izopet J; Baron E; Duffaut M; Puel J; Durand D
    Transplantation; 1995 May; 59(10):1426-31. PubMed ID: 7770930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C.
    Nakamura K; Yoneda M; Takamoto S; Nakade Y; Yokohama S; Tamori K; Aso K; Matui T; Sato Y; Aoshima M; Makino I
    J Gastroenterol Hepatol; 1999 May; 14(5):413-8. PubMed ID: 10355503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Procollagen-III peptide and chronic viral C hepatitis.
    Jeffers LJ; Coelho-Little ME; Cheinquer H; Vargas C; Civantos F; Alvarez L; Reddy KR; Parker T; de Medina M; Li X
    Am J Gastroenterol; 1995 Sep; 90(9):1437-40. PubMed ID: 7661165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of ursodeoxycholic acid in acute viral hepatitis.
    Galský J; Bansky G; Holubová T; Kõnig J
    J Clin Gastroenterol; 1999 Apr; 28(3):249-53. PubMed ID: 10192613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
    J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes of serum hepatitis C virus levels in patients with chronic hepatitis C treated with two courses of interferon administration.
    Saitoh Y; Miura M; Niitsuma H; Numata N; Ohori H; Ishii M; Toyota T
    Tohoku J Exp Med; 1994 Aug; 173(4):361-9. PubMed ID: 7529950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of hepatitis C RNA and serum alanine aminotransferase in hepatitis B and C seronegative healthy blood donors.
    Ali N; Moiz B; Moatter T; Ahmed S; Adil SN; Khurshid M
    Indian J Pathol Microbiol; 2010; 53(3):480-5. PubMed ID: 20699507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short and long-term effects of interferon on serum markers of hepatitis C virus replication.
    Yatsuhashi H; Inoue O; Inokuchi K; Koga M; Nagataki S; Cha TA; Irvine B; Stempien M; Kolberg J; Urdea MS
    J Gastroenterol Hepatol; 1993; 8(1):1-6. PubMed ID: 8382537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.